Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...